180 related articles for article (PubMed ID: 35279508)
1. Patient-reported outcomes one year after positive sentinel lymph node biopsy with or without axillary lymph node dissection in the randomized SENOMAC trial.
Appelgren M; Sackey H; Wengström Y; Johansson K; Ahlgren J; Andersson Y; Bergkvist L; Frisell J; Lundstedt D; Rydén L; Sund M; Alkner S; Vrou Offersen B; Filtenborg Tvedskov T; Christiansen P; de Boniface J;
Breast; 2022 Jun; 63():16-23. PubMed ID: 35279508
[TBL] [Abstract][Full Text] [Related]
2. The generalisability of randomised clinical trials: an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer.
de Boniface J; Ahlgren J; Andersson Y; Bergkvist L; Frisell J; Lundstedt D; Olofsson Bagge R; Rydén L; Sund M;
Breast Cancer Res Treat; 2020 Feb; 180(1):167-176. PubMed ID: 31989379
[TBL] [Abstract][Full Text] [Related]
3. Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial.
de Boniface J; Frisell J; Andersson Y; Bergkvist L; Ahlgren J; Rydén L; Olofsson Bagge R; Sund M; Johansson H; Lundstedt D;
BMC Cancer; 2017 May; 17(1):379. PubMed ID: 28549453
[TBL] [Abstract][Full Text] [Related]
4. Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment.
Tinterri C; Canavese G; Gatzemeier W; Barbieri E; Bottini A; Sagona A; Caraceni G; Testori A; Di Maria Grimaldi S; Dani C; Boni L; Bruzzi P; Fernandes B; Scorsetti M; Zambelli A; Gentile D;
Br J Surg; 2023 Aug; 110(9):1143-1152. PubMed ID: 37471574
[TBL] [Abstract][Full Text] [Related]
5. A patient- and assessor-blinded randomized controlled trial of axillary reverse mapping (ARM) in patients with early breast cancer.
Beek MA; Gobardhan PD; Klompenhouwer EG; Menke-Pluijmers MB; Steenvoorde P; Merkus JW; Rutten HJ; Voogd AC; Luiten EJ
Eur J Surg Oncol; 2020 Jan; 46(1):59-64. PubMed ID: 31402072
[TBL] [Abstract][Full Text] [Related]
6. Management of the Axilla in T1-2 Breast Cancer Patients with Macrometastatic Sentinel Node Involvement Who Underwent Breast-Conserving Therapy.
Kuru B; Yuruker S; Sullu Y; Gursel B; Ozen N
J Invest Surg; 2019 Jan; 32(1):48-54. PubMed ID: 28945489
[TBL] [Abstract][Full Text] [Related]
7. Axillary lymph node dissection vs. sentinel node biopsy for early-stage clinically node-negative breast cancer: a systematic review and meta-analysis.
Petousis S; Christidis P; Margioula-Siarkou C; Liberis A; Vavoulidis E; Margioula-Siarkou G; Vatopoulou A; Papanikolaou A; Mavromatidis G; Dinas K
Arch Gynecol Obstet; 2022 Oct; 306(4):1221-1234. PubMed ID: 35249123
[TBL] [Abstract][Full Text] [Related]
8. A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial.
Zavagno G; De Salvo GL; Scalco G; Bozza F; Barutta L; Del Bianco P; Renier M; Racano C; Carraro P; Nitti D;
Ann Surg; 2008 Feb; 247(2):207-13. PubMed ID: 18216523
[TBL] [Abstract][Full Text] [Related]
9. Trends in axillary treatment for breast cancer patients undergoing sentinel lymph node biopsy as determined by a questionnaire from the Japanese Breast Cancer Society.
Imoto S; Yamauchi C; Komoike Y; Tsugawa K; Yotsumoto D; Wada N; Ueno T; Oba MS; Shien T; Sugae S; Tsuda H; Yoneyama K
Breast Cancer; 2017 May; 24(3):427-432. PubMed ID: 27553957
[TBL] [Abstract][Full Text] [Related]
10. Impact of modern-day axillary treatment on patient reported arm morbidity and physical functioning in breast cancer patients.
Gregorowitsch ML; Verkooijen HM; Houweling A; Fuhler N; Koelemij R; Schoenmaeckers EJP; Sier MF; Ernst MF; Witkamp AJ; Van Dalen T; Young-Afat DA; van den Bongard DHJG;
Radiother Oncol; 2019 Feb; 131():221-228. PubMed ID: 30033384
[TBL] [Abstract][Full Text] [Related]
11. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
[TBL] [Abstract][Full Text] [Related]
12. Comparison of quality of life and arm complaints after axillary lymph node dissection vs sentinel lymph node biopsy in breast cancer patients.
Peintinger F; Reitsamer R; Stranzl H; Ralph G
Br J Cancer; 2003 Aug; 89(4):648-52. PubMed ID: 12915872
[TBL] [Abstract][Full Text] [Related]
13. Does the presence of sentinel lymph node macrometastases in breast cancer patients require axillary lymph node dissection?-Single-center analysis.
Nowikiewicz T; Zegarski W; Pagacz K; Nowacki M; Morawiec-Sztandera A; Głowacka-Mrotek I; Sowa M; Biedka M; Kołacińska A
Breast J; 2018 Sep; 24(5):724-729. PubMed ID: 29476570
[TBL] [Abstract][Full Text] [Related]
14. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial.
Henke G; Knauer M; Ribi K; Hayoz S; Gérard MA; Ruhstaller T; Zwahlen DR; Muenst S; Ackerknecht M; Hawle H; Fitzal F; Gnant M; Mátrai Z; Ballardini B; Gyr A; Kurzeder C; Weber WP
Trials; 2018 Dec; 19(1):667. PubMed ID: 30514362
[TBL] [Abstract][Full Text] [Related]
15. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
Boughey JC; Suman VJ; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Kuerer HM; Bowling M; Flippo-Morton TS; Byrd DR; Ollila DW; Julian TB; McLaughlin SA; McCall L; Symmans WF; Le-Petross HT; Haffty BG; Buchholz TA; Nelson H; Hunt KK;
JAMA; 2013 Oct; 310(14):1455-61. PubMed ID: 24101169
[TBL] [Abstract][Full Text] [Related]
16. Conservative axillary surgery is emerging in the surgical management of breast cancer.
Noguchi M; Inokuchi M; Yokoi-Noguchi M; Morioka E; Haba Y
Breast Cancer; 2023 Jan; 30(1):14-22. PubMed ID: 36342647
[TBL] [Abstract][Full Text] [Related]
17. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.
Classe JM; Loaec C; Gimbergues P; Alran S; de Lara CT; Dupre PF; Rouzier R; Faure C; Paillocher N; Chauvet MP; Houvenaeghel G; Gutowski M; De Blay P; Verhaeghe JL; Barranger E; Lefebvre C; Ngo C; Ferron G; Palpacuer C; Campion L
Breast Cancer Res Treat; 2019 Jan; 173(2):343-352. PubMed ID: 30343457
[TBL] [Abstract][Full Text] [Related]
18. Morbidity in breast cancer patients with sentinel node metastases undergoing delayed axillary lymph node dissection (ALND) compared with immediate ALND.
Goyal A; Newcombe RG; Chhabra A; Mansel RE
Ann Surg Oncol; 2008 Jan; 15(1):262-7. PubMed ID: 17879117
[TBL] [Abstract][Full Text] [Related]
19. Role of frozen section in sentinel lymph node biopsy for breast cancer in the era of the ACOSOG Z0011 and IBCSG 23-10 trials.
Lombardi A; Nigri G; Maggi S; Stanzani G; Vitale V; Vecchione A; Nania A; Amanti C
Surgeon; 2018 Aug; 16(4):232-236. PubMed ID: 29329752
[TBL] [Abstract][Full Text] [Related]
20. Axillary dissection in sentinel lymph node positive breast cancer: Is the staging information worthwhile for patients?
Chang DW; Bressel M; Hansen C; Blinman P; Schofield P; Chua BH
Asia Pac J Clin Oncol; 2021 Apr; 17(2):e27-e34. PubMed ID: 31461222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
